ArticleFrontiers in immunology2025
Epitope-level analysis of cross-reactive human HLA antibodies against genetically modified swine leukocyte antigens in xenotransplantation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding the structure of swine leukocyte antigen class I molecules.Cellular & molecular biology letters · 2026Review
- Present Advances and Emerging Challenges in Kidney Xenotransplantation.Journal of clinical medicine · 2026Review
- Xenotransplantation Literature Update: January-June 2026.XenotransplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Xenotransplantation using genetically modified pigs is a promising solution to organ shortages, particularly for highly sensitized patients with broad anti-HLA sensitization who lack compatible allografts. However, preformed human anti-HLA antibodies may cross-react with porcine SLA, posing a barrier for clinical application. This study aims to characterize the extent and specificity of cross-reactive antibody responses against genetically engineered pig PBMCs, particularly from quadruple knockout (QKO) pigs. Methods: We evaluated antibody binding and cytotoxicity of 68 human sera stratified by HLA class I and II antibody profiles using flow cytometric crossmatch (FCXM), complement-dependent cytotoxicity (CDC) assays (CDC-NIH and CDC-AHG), antibody elution, and single antigen bead assays. Porcine PBMCs from wild-type and gene-edited pigs (GTKO, TKO, QKO) were used. High-resolution SLA epitope mapping was performed with antibody eluted from select sera followed by in silico sequence and structural analyses. Results: Human sera showed strong IgG and IgM binding to wild-type pig PBMCs, which was significantly reduced by RBC adsorption, whereas binding to QKO pig PBMCs lacking key glycan xenoantigens was minimal and unaffected by RBC adsorption. Sensitized human sera with both HLA class I and II antibodies demonstrated significantly elevated IgG binding to QKO pig PBMC T and B cells compared to antibody-negative sera (p < 0.05). CDC-AHG assays revealed increased cytotoxicity titers (≥1:8) in HLA antibody-positive sera versus negatives (p < 0.01). Antibody elution from five crossmatch-positive sera identified predominant class I eplets (62EE, 162GLS, 163LG, 163LS/G, 166ES, 199V) and class II DR epitopes (13SE, 37F, 47F, 70D, 70DA) that target SLA 4.5/6.7 haplotypes. In contrast, anti-HLA-DQ and -DP reactivity was limited post-elution. Structural modeling confirmed that these epitopes are conserved and surface-exposed in SLA alleles. Conclusion: Cross-reactive anti-SLA antibodies are common in highly sensitized human sera, driven by antibody specificity and epitope conservation. Despite glycan xenoantigen deletion, sensitized sera maintain IgG-mediated cross-reactivity and cytotoxicity against gene-edited pig cells. These findings highlight the need for detailed epitope-level analysis to refine immunologic risk assessment and recipient selection to reduce antibody-mediated rejection in clinical xenotransplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.